Harmine (GMP)

Harmine (GMP) (Telepathine (GMP)) is Harmine (HY-N0737A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT_2A serotonin receptor, with an K_i of 397 nM^[1]. In Vitro:Harmine (GMP) inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC₅₀ of 190 nM^[2]. Harmine (GMP) negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine^[3]. In Vivo:It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine (GMP) significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine (GMP) treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine (GMP) significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine (GMP) treatment. The neuronal survival rate in the Harmine (GMP)-treated group is significantly increased, compared with the TBI group. Administration of Harmine (GMP) results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine (GMP) significantly reduces the expression of caspase 3, compared with the TBI group^[4].